Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 6.6%
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) was a big mover last session, as its shares rose almost 7% on the day. The rally came on the back of the company’s agreement with the FDA on a confirmatory Phase 3 study protocol for Firdapse in Lambert-Eaton myasthenic syndrome (LEMS). This led to far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up 10% in the past one-month time frame.
Over the last 30 days, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Catalyst Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
CATALYST PHARMA Price
CATALYST PHARMA Price | CATALYST PHARMA Quote
A better-ranked med-drugs stock is Juniper Pharmaceuticals, Inc. , sporting a Zacks Rank #1(Strong Buy).
Is CPRX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>